The ALLG is an Australian not-for-profit, public unlisted company limited by guarantee and is a registered charity.
ALLG Board of Management
The ALLG is governed on behalf of members by a Board of Management in accordance with the ALLG Constitution. Subject to the exercise by the Board of the powers contained in the ALLG Constitution, the Board manages the company and directs the affairs of the company. Current Board members are:
Mr
AM, FCA, FAICD
Chairman of the Board
Peter was appointed to the Board as a Director and Chairman in early 2010. He is a member of the Finance and Audit Committee of the Board.
Professor
BHB, MBChB, FRACP, FRCPA, PostGrad Cert Clin Res (Oncology)
Director
Judith has been a prominent ALLG Member for more then 20 years and was a Scientific Advisory Committee (SAC) representative member from 2014 – 2019. She was appointed as the Chair of the SAC in October 2022.
Ms
BA, LLB, LLM
Director
Geraldine was appointed to the Board as a Director in early 2010. She is a barrister of more than 30 years, with a particular experience in health law.
Ms
Bachelor of Commerce, Chartered Management Accountant and Post Graduate Diploma of Applied Finance
Director
Lisa Keenan was elected as a Director of the ALLG in October 2020.
Mr
BEc, LLB, SF Fin, FAICD
Director
Malcolm was elected to the Board, and has performed the role of Chairman of the Finance and Audit Committee of the Board, since May 2010.
Ms
Dip Diag Rad (Sturt CAE), Grad Dip Mgmt (RMIT), MBus (Swinburne)
Director
Tina was elected to the ALLG Board as a Director in early 2013 with aims to embed fund-raising as a core operational activity utilising her skills, experience and networks.
Professor
MBBS, PhD, FRACP, FRCPA
Director
Andrew has been a Director with the ALLG Board since 2010, and has served on several other not-for-profit boards.
Professor
MBBS, FRACP, FRCPA, MS
Director
Phil was elected to the Board as a Director in October 2016. He has over 30 years research experience in clinical trials of new treatments, biostatistical analyses of large datasets in blood and marrow transplant for leukaemia, multiple myeloma, lymphoma and other malignancies.
Professor
BMedSci, MBChB, FRACP, FRCPA
Director
Peter has been an active member of the Company since April 1997. He currently chairs the Safety and Data Monitoring Committee (SDMC).